Uncategorized
Low-dose bevacizumab may be effective, safer for ROP
NASHVILLE, Tenn. — Bevacizumab doses that are a fraction of those studied in the BEAT-ROP trial may be successful in treatment of type 1 retinopathy of prematurity, according to a speaker here.“The 0.625 mg dosage, which is commonly used, is certainly a reasonable starting point, but it’s probably much more than is necessary,” David K. Wallace, MD, MPH, told colleagues at the American Association for Pediatric Ophthalmology and Strabismus meeting, where he reported results of a phase 1 dose de-escalation study.